admin

Intec Pharma Ltd (NASDAQ:NTEC) stock price target has been raised by Oppenheimer to $15.00 from $10.00 while maintaining the Outperform rating. The analyst Jay Olson has noted that the shares are up 60% since June and expects further upside as Accordion resonates with investors. Further the analyst Olson noted the clinical and operational progress that […]

by

It may be one of the world’s oldest drugs, but cannabis has caught the world unprepared. After 80 years of draconian prohibition, the tide has suddenly turned. Medicinal cannabis is flooding in and overwhelming the medical establishment, as patients clamour for it, many convinced it is a harmless cure-all to their ills. Some 2.3 million […]

by

NEW YORK, September 19, 2017 /PRNewswire/ — The hazards of pharmacology have hardly changed since Paracelsus, a famous Renaissance physician, astoundingly declared that it was only the dosage that separated a medicine from a poison, bundled with adverse side effects. Despite considerable advances in medicine, many medications are still as injurious as their Renaissance precursors. […]

by

TORONTO, ONTARIO–(Marketwired – Sept. 19, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has entered into a license agreement with South Carolina Research Foundation (“SCRF”), under which Revive will acquire […]

by

Medicine bottle image: monicore A small observational trial of the use of medicinal cannabis extracts in treating autism has returned positive results. Australia’s Zelda Therapeutics sponsored a trial in Chile involving 21 patients, who were treated over at least three months. According to the company, results of the trial indicate cannabis extracts are more effective […]

by

TORONTO, ONTARIO–(Marketwired – Sept. 19, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has entered into a license agreement with South Carolina Research Foundation (“SCRF”), under which Revive will acquire […]

by

NEW YORK, September 19, 2017 /PRNewswire/ — The hazards of pharmacology have hardly changed since Paracelsus, a famous Renaissance physician, astoundingly declared that it was only the dosage that separated a medicine from a poison, bundled with adverse side effects. Despite considerable advances in medicine, many medications are still as injurious as their Renaissance precursors. […]

by

Whole-plant marijuana and its products are already used during palliative care outside of the traditional hospice and hospital settings. Santa Cruz, California, is home to the Wo/Men’s Alliance for Medical Marijuana, a cannabis collective that has been compared to a traditional hospice. Director Valerie Corral helped pass the country’s first medical cannabis law in part […]

by

GW Pharmaceuticals is closing in on a US filing for its cannabinoid epilepsy drug, Epidiolex, after trumpeting late-stage study findings. The company specialises in drugs derived from the cannabis plant, and noted that the New England Journal of Medicine had published results from its phase 3 study of Epidiolex (cannabidiol) in the rare childhood epilepsy, Dravet Syndrome. […]

by

Brazilian doctors have begun prescribing HempMeds Brasil‘s hemp cannabis oil to ALS and psoriasis patients, the company’s U.S. parent reports. San Diego-based Medical Marijuana said it is the first time Brazilian physicians have prescribed the product, known as Real Scientific Hemp Oil, to those with the two diseases. HempMeds Brasil has been providing medical cannabis to patients for […]

by

A phase 2 trial of Zynerba Pharmaceuticals’ transdermal cannabinoid candidate has missed all its endpoints. The failure of the study to hit a single goal or show a dose response raises big doubts about the drug’s prospects—and wiped more than 55% off Zynerba’s stock price. Investigators enrolled 188 adults with refractory epilepsy with focal seizures and […]

by